Introduction
Bcr-Abl, a chimeric oncogene, is formed by a reciprocal translocation between chromosomes 9 and 22 (Philadelphia chromosome, Ph 1 ), that places the c-ABL gene under the transcriptional control of the BCR gene 1, 2 , resulting in the constitutive activation of c-Abl tyrosine kinase 3, 4 . Depending on the breakpoint site in the Bcr gene, two variants of the Bcr-Abl fusion proteins are generated 5 . The p210 Bcr-Abl is present in virtually all cases of chronic myelogenous leukemia (CML), while the p185 product is present in approximately 20% of acute lymphoblastic leukemias 6 . The Bcr-Abl tyrosine kinase activates a number of downstream cell signaling pathways resulting in growth factor-independent cell proliferation, altered cell adhesion and resistance to apoptosis induced by other chemotherapeutic agents 7 . The recently developed inhibitor of Bcr-Abl kinase activity, Imatinib mesylate, induces a high percentage of complete hematologic responses and partial or complete cytogenetic remissions in chronic phase CML 8, 9 .
Imatinib has high affinity for Bcr-Abl tyrosine kinase 10 and inhibits its activity by binding to its ATP-binding pocket 11 . Despite a high degree of selectivity, approximately 60% of CML patients retain the Ph 1 chromosome after 18 months on Imatinib treatment 12 and more than 90% remain positive for Bcr-Abl transcripts, as measured by the quantitative real-time polymerase chain reaction assay 13 . Residual Bcr-Abl positivity is clearly linked to risk for disease progression and the development of blast crisis.
Resistance to Imatinib eventually develops in the majority of patients treated in the blast crisis stage of the disease, primarily due to the emergence of point mutations in or amplification of the Bcr-Abl gene 14 . The emergence of Imatinib resistance creates a strong incentive to find non-toxic approaches to enhance its efficacy, including combining Imatinib with a drug that enhances its cytotoxicity.
Inosine monophosphate dehydrogenase (IMPDH; EC1.1.1.205) is an essential, rate-limiting enzyme for the generation of guanine nucleotides through the de novo synthesis pathway. It catalyzes the NAD-dependent conversion of inosine monophosphate to xanthine monophosphate, which is subsequently converted to guanosine monophosphate (GMP) by GMP synthase. The only alternative pathway for guanine nucleotide biosynthesis is through the salvage of guanine to GMP by hypoxanthine-guanine phosphoribosyltransferase. IMPDH enzyme activity is composed only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From of the activities of two separate but very closely related IMPDH isoenzymes, termed type I and type II, that share 84% amino acid identity 15 . Expression of IMPDH, particularly the type II enzyme, is significantly upregulated in many tumor cells, including leukemia cells [16] [17] [18] [19] , presumably to meet a high demand for guanine nucleotides during cell proliferation. Reduction of guanine nucleotides by inhibiting IMPDH activity effectively induces cell cycle arrest in late G1 phase in lymphocytes 20, 21 and results in differentiation [22] [23] [24] or apoptosis [25] [26] [27] in cultured cell lines depending on the cell type. The fact that these effects on cell growth and differentiation are completely reversed by the addition of guanine or guanosine to the medium demonstrates that the effects of IMPDH inhibitors are specifically due to guanine nucleotide depletion. Inhibitors of IMPDH have been used clinically as immunosuppressive agents [28] [29] [30] and have also been used to induce hematologic responses in patients with CML in blast crisis 31, 32 and in Bcr-Abl positive AML patients 33 . However, the reduction in blast count is temporary and other studies have suggested that IMPDH inhibitors may be better used in combination with other chemotherapeutic drugs 34, 35 .
In the present study, we have demonstrated that a specific IMPDH inhibitor, Mycophenolic Acid (MPA), can significantly enhance Imatinib cytotoxicity in Bcr-Abl positive cells. We have also investigated the possible Bcr-Abl signaling pathways affected by combining a specific inhibitor of Bcr-Abl tyrosine kinase with guanine nucleotide depletion.
Materials and Methods

Recombinant retroviral infection
The pSRMSVtkneo plasmid, containing the p185 form of Bcr-Abl was kindly provided by Dr. C. Der (Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill). Retrovirus was produced in 293T cells using pVpack system (Stratagene, La Jolla, CA). Both 32D and FL5.12 cells were infected with control retrovirus alone or retrovirus encoding the p185 Bcr-Abl fusion gene. Cells were selected and maintained in the presence of 500 µg/ml G418. The p185 Bcr-Ablexpressing cells were also selected for growth independent of IL-3.
Cell lines and reagents
The murine myeloid cell line 32D was maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS, Hyclone, Logan, UT) and 10% WEHI conditioned medium as a source of IL-3. The murine pre-B cell line FL5.12 (a gift from C. B. Thompson, University of Pennsylvania, Philadelphia) was maintained in RPMI-1640 medium supplemented with 10% heat-inactivated FBS, 20 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), 55 µM 2-mercaptoethonal, and 10% WEHI conditioned medium. Human leukemia cell lines K562, HL60 and U937 (originally obtained from ATCC, Rockville, MD) were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated FBS. An Imatinib-resistant K562 derivative cell line K562R and LAMA84 cells were generously provided by Dr. S. Grant (Commonwealth University, Richmond, Virginia). LAMA84 cells were maintained in RPMI-1640 medium (without phenol-red) supplemented with 0.1 mM MEM nonessential amino acid (Gibco, Caraday, CA), 2 mM L-glutamine (Gibco) and 1 mM MEM sodium pyruvate (Gibco). All cell cultures were maintained in the presence of 100 µg/ml penicillin and streptomycin. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From drug 1 and drug 2 in combination required to produce the same effect 36, 37 . CI was used to express synergism (CI<1), additive effect (CI=1) or antagonism (CI >1). 
Annexin
Western immunobloting
To prepare cell lysates for Western immunoblot analysis, cell pellets were lysed in buffer containing 20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 10% Glycerol, 1% TritonX-100, 1 mM Na 3 VO 4 , 25 mM -glycerophosphate, 1x protease inhibitor cocktail and 1x phosphatase inhibitor cocktail 1 (Sigma). After centrifugation at 14,000 x g for 15 min, protein concentrations were quantitated in duplicate by the Bradford method (Bio-Rad . The two drugs were used in constant ratios in most MTT assays to generate classical isobolograms. In some instances, non-constant ratios were also tested to determine the effectiveness of a broader range of combinations (data not shown). The CI values at ED50, ED75 and ED90 generated from classical isobolograms for all four Bcr-Abl positive cell lines are summarized in Table 2 . 
Effect of MPA and Imatinib combinations on the induction of apoptosis
To determine whether combined treatment with MPA and Imatinib also enhances apoptosis, 32D-p185 and K562 cells were treated with various concentrations of MPA and/or Imatinib followed by Annexin V staining and analyzed by flow cytometry. Each drug alone at the doses used induced very little or no apoptosis; however, the combination of the two greatly increased the percentage of Annexin V-positive cells in both cell lines (Fig. 1) . To determine the CI values for apoptosis, at least 4 doses of each drug was used in every experiment to generate single drug curves. Highly synergistic effects were observed for multiple combination treatments in both 32D-p185 and K562 cell lines (Table 3) . Interestingly, the CI values for apoptosis demonstrate far more synergy than do the cell growth inhibition experiments. This is most likely because each drug alone can significantly inhibit growth but only induce very low levels of apoptosis at the concentrations used. The reduction in live cells, as defined by both Annexin V and PI negativity, for each combination treatment as compared to each drug alone was also statistically significant (p<0.05) using a paired two-tailed Student t test analysis on three independent experiments (data not shown).
Specificity of induction of apoptosis for Bcr-Abl-positive cells
To determine whether the induction of apoptosis by combined treatment with MPA and Imatinib is specific for Bcr-Abl expressing cells, we treated vector control or Bcr-Ablexpressing-32D and FL5.12 cells with MPA and/or Imatinib for 16 to 20 hrs and fragmented DNA was analyzed using the Cell Death Detection ELISA method 27 . The level of apoptosis induced by the combination treatment in vector-control cells was similar to that of MPA alone, whereas the combination markedly enhanced apoptosis in Bcr-Abl expressing-cells (Fig. 2) . Apoptosis was also evaluated by the size of the sub-G1 peak obtained from cell cycle analysis. Bcr-Abl positive FL5.12 and LAMA84 cells and Bcr-Abl negative HL-60 and U937 cells were analyzed by flow cytometry after only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From single and combination drug treatment (Fig. 3) . In both FL5.12-p185 and LAMA cells, MPA and Imatinib alone induced a small increase in the sub-G1 peak, whereas this peak was markedly increased by the combination treatment. In HL-60 and U937 cells, Imatinib (4uM) did not induce the apoptotic sub-G1 peak, nor did it enhance the MPA effect.
Synergistic activity in K562 cells resistant to Imatinib
To determine whether MPA also enhance the response to Imatinib in cells that
demonstrate Imatinib resistance, we tested the effect of the combination on induction of apoptosis using a K562 derivative cell line selected in the presence of Imatinib .
Effect of combination treatment on phospho-Jak2 and phospho-Src expression
We next examined upstream molecules that could phosphorylate Stat5. We failed to identify significant amounts of constitutively activated Janus kinase (Jak) 2 protein in our Bcr-Abl expressing cell lines, and did not detect any significant effect on phospho-Jak2 levels by either single or combination drug treatment (data not shown), suggesting that Jak2 is not responsible for the effect on Stat5 phosphorylation. This result is also consistent with the previous finding that inhibition of Jak2 does not affect Stat5 activity , and have been implicated in Bcr-Abl-mediated transformation 38, 47 . We have found that levels Src phosphorylation in 32D and FL5.12 cells were very high independent of the expression of p185 Bcr-Abl, most likely due to the continuous IL-3 stimulation required for the growth of vector-control cells. However, Src is more highly phosphorylated in the human Bcr-Abl positive cell lines, K562 and LAMA84 cells, than in HL-60 and U937 cells (data not shown). Although neither drug by itself significantly decreased p-Src levels, the combination dramatically reduced Src phosphorylation in 32D-p185 and FL5.12-p185 cells after 90 min (Fig. 6A) . Similar, although less dramatic, reductions were observed after 24 hrs of combined treatment of K562 and LAMA cells (Fig. 6A) . The antibody used to detect p-Src (Y416) detects several activated Src family members, including Lyn (Y396, p53/p56) and Hck (Y390, p59). When the blots were probed with total Lyn, Hck or Src antibodies, two bands detected by the Lyn antibody, p53 and p56, corresponded precisely to the two bands
detected by p-Src antibody. In contrast, Hck-specific antibody demonstrated a single slightly higher band, the p59 protein, while Src-specific antibody also recognized a p60 protein. To confirm that the reduction in phosphorylation is that of Lyn, we performed immunoprecipitation using anti-Lyn antibody followed by Western blot analysis with a tyrosine phosphorylation-specific antibody (Fig. 6B) . These results clearly demonstrated that Lyn phosphorylation is reduced by the combination treatment.
Effect of combination treatment on mTOR pathway
It has been shown that the mammalian target of Rapamycin (mTOR) pathway is activated in Bcr-Abl transformed cells (Fig. 7) .
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For Our hypothesis is that guanine nucleotide depletion has a central sensing mechanism with multiple downstream effectors, ultimately resulting in growth arrest or apoptosis.
Although this molecular sensor has not been definitively identified, we are exploring several small GTP binding proteins as candidates. One, the Rheb GTPase, was initially isolated as a Ras homolog enriched in brain 67 and directly activates the mTOR pathway 68 . Transient expression of a wild-type Rheb induces a dramatic increase in S6K phosphorylation and mobility shift of 4EBP1, and this high level of activity is consistent with its being predominantly GTP bound 68 . A dominant negative Rheb, defective in GTP binding, was found to block nutrient and serum-induced p70 S6K activation For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From the probability that this combination will be effective in patients, since Imatinib will inhibit purine salvage. The proposed clinical trial will be the optimal approach to definitively test our hypothesis and will incorporate the specific molecular endpoint of a greater than 1 log reduction in the Bcr-Abl transcript six months after the addition of
MPA.
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